Overview

Sirolimus & Mycophenolate Mofetil as GVHD Prophylaxis in Myeloablative, Matched Related Donor HCT

Status:
Completed
Trial end date:
2010-04-01
Target enrollment:
Participant gender:
Summary
GVHD prophylaxis of sirolimus and mycophenolate mofetil for patients undergoing matched related allogeneic transplant for acute and chronic leukemia, MDS, high risk NHL and HL
Phase:
Phase 2
Details
Lead Sponsor:
Stanford University
Collaborator:
National Institutes of Health (NIH)
Treatments:
Busulfan
Carmustine
Cyclophosphamide
Etoposide
Everolimus
Mycophenolate mofetil
Mycophenolic Acid
Sirolimus